Fig. 6: Revitalizing type 2low CAR T cells through enhanced type 2 functionality boost.
From: Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
a, Schematic of the two strategies used to enhance the type 2 functionality of type 2low CAR T cells derived from the donor ND585. The diagram was created using BioRender. b, The tumour burden was measured using bioluminescence at the indicated days after CAR T cell infusion. GVHD, graft-versus-host disease. c, CAR T cell expansion in the peripheral blood of Nalm6-bearing mice measured at different timepoints after infusion. Data are mean ± s.e.m. from n = 5 mice for each group. d, Kaplan–Meyer analysis of mouse survival. Significance levels were calculated using one-way ANOVA with Tukey’s multiple-comparison test (c) or log-rank Mantel–Cox test (d).
